News

The value of attending industry meetings at the beginning of a career in ophthalmology.

Navigating the labyrinth of IRD research to identify objective, clinically meaningful outcomes.

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care.

As artificial intelligence tools become more common in research, students must navigate issues including plagiarism, data consent, and equitable application.

Panel examines drug mechanisms, patient factors, and strategies to optimize results.

Real-world insights guide the way to tailored treatment.

A trio of retina specialists recently reviewed the clinical benefits of aflibercept 8 mg, including its extended dosing intervals, improved patient satisfaction, and enhanced treatment outcomes for various conditions.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

This approach helps distinguish diseases associated with macular atrophy.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

NCX 470 is Nicox’s lead dual-mechanism bimatoprost eye drop for lowering IOP in open-angle glaucoma or ocular hypertension.

Insights for diagnosing and managing these visible changes across specialties.

Explore the evolving challenges and insights in long-term follow-up for pediatric gene therapy, focusing on data integrity, ethical considerations, and patient retention.

AI revolutionizes retinal care, enhancing diagnosis, monitoring, and treatment through innovative technologies and collaborative efforts in ophthalmology.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

Dr. Curcio highlights volume electron microscopy evidence from a preterm-born adult retina reveals unexpected Müller glial diversity and implications for foveal development.

Tips for optimizing surgical techniques to reduce recurrence and enhance outcomes.

Lock in patient adherence with discussion of study results.

Results showed reduction in geographic atrophy progression and improved visual acuity.

The trial is being discontinued based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for “futility."

While primary endpoint analysis showed no statistical difference in the rate of change in GA area between AVD-104 versus monthly avacincaptad pegol, 12-month results showed approximately 31% reduction in GA lesion growth rate versus growth rates in sham and natural history rates.